3 ms·
Waldmann/Ginn don't describe the FDA's complaints about the competitors, but it's probably: (1) a failure to validate claims or (2) insufficient design/manufact
by wyldfire 10y ago
Waldmann/Ginn don't describe the FDA's complaints about the competitors, but it's probably: (1) a failure to validate claims or (2) insufficient design/manufacturing controls. IMO it's very unlikely that the FDA is engaged in protectionism of the sole manufacturer of this product.
> Most definitely, the solution is not more government controls through regulation.
I agree that we likely don't need any more regulation in this space. But it seems obvious to me that this issue is related to the overall shift lately. Employers are offering high-deductible insurance plans and employees are bearing a greater burden. The outrage over EpiPens is just another symptom of the US public clamoring for what they see as something that should be an entitlement. I don't know that I prefer it but it seems pretty clear to me that it's coming (within another generation or two at max).
The point about patent protection is pretty huge. I wonder: what net effects would there be to removing patents entirely? Would we end up with less ambitious products and services because designs would just get copied by the cheapest production centers? Could we/should we restrict patents among different industries?